Abstract Details

<< Back to Detailed Agenda

8/23/2022  |   3:30 PM - 4:30 PM   |  Governor General I

CMV Prevention: What's Taking So Darn Long

A brief discussion of how the incremental building of scientific evidence is required for a new vaccine or drug (i.e., preclinical studies, phase 1, 2, 3 trials), the safety/efficacy evidence that is needed before licensure or acceptance, and the time and costs involved. CMV-specific challenges, the increased safety concerns around interventions during pregnancy, the lack of universal CMV screening, and the lack of CMV awareness by women and policymakers.

Presentation:
This presentation has not yet been uploaded.

Handouts:
No handouts have been uploaded.

Session Evaluation

Karen B. Fowler (Primary Presenter), kfowler@uab.edu;
Dr. Fowler is a Professor in the Division of Infectious Diseases in the Department of Pediatrics at the University of Alabama at Birmingham.

ASHA DISCLOSURE: Financial - Nonfinancial -

AAA DISCLOSURE: Financial - No relevant financial relationship exists.

Isabelle Boucoiran (POC-Point of Contact,Primary Presenter), isabelle.boucoiran@umontreal.ca;
Isabelle Boucoiran is a maternofetal medicine and reproductive infectious disease specialist as well as a clinician scientist.

ASHA DISCLOSURE: Financial - No relevant financial relationship exists. Nonfinancial - No relevant nonfinancial relationship exists.

AAA DISCLOSURE: Financial - No relevant financial relationship exists.

Soren Gantt (Co-Presenter), soren.gantt.med@ssss.gouv.qc.ca;
Dr. Gantt is a Pediatric Infectious Diseases specialist, the Director of Clinical Research at CHU Sainte-Justine, and Full Professor in the Departments of Microbiology, Infectious Diseases & Immunology and of Pediatrics at the University of Montreal. Dr. Gantt’s current research focuses primarily on the development of CMV vaccines as well as newborn CMV screening programs.

ASHA DISCLOSURE: Financial - Receives Consulting fee, Grants for Consulting, Independent contractor (including contracted research) from Moderna, Merck, GSK, VBI Vaccines, Altona Diagnostics.   Nonfinancial - No relevant nonfinancial relationship exists.

AAA DISCLOSURE: Financial - Receives support from Moderna, Merck, GSK, VBI Vaccines, Altona Diagnostics for Consulting and research funding related to CMV vaccine development.